Lexaria Bioscience Corp. (NASDAQ: LEXX), Growing its Market Share, One Patent at a Time

• Lexaria’s development of its patented DehydraTECH(TM) technology since 2014 has yielded 27 patents in Australia, the United States, the European Union, Japan, India and Mexico with approximately 50 additional patents pending around the world
• Its latest patent, granted in Mexico, applies a range of active ingredients, including but not limited to non-psychoactive cannabinoids and NSAIDs in a variety of ready-to-drink consumer retail beverage products
• Lexaria remains committed to advancing its research and expanding the indications and efficacy of its DehydraTECH technology, as it looks to benefit from the CBD industry, projected to be valued at $111.8 billion by 2030, and the cardiovascular drugs market, projected to be valued at $107.8 billion by 2025

Since Lexaria Bioscience (NASDAQ: LEXX) began the development of its industry-leading DehydraTECH(TM) technology back in 2014, the company has remained steadfast in its goal to improve the way active pharmaceutical ingredients (“APIs”) enter the bloodstream. Moreover, as a global innovator in drug delivery platforms, the company has not shied away from advancing its research to cut across various health conditions, including but not limited to hypertension, epilepsy, diabetes and dementia, among others.

These efforts have yielded 27 granted patents around the world since 2014, with approximately 50 additional patents pending. It also has national filings in over 40 jurisdictions with the highest commercial potential, reflecting the company’s commitment to creating shareholder value and pushing its technology further into the market (https://ibn.fm/imFGA).

Its latest patent, granted in Mexico under registration #390001, applies to a range of active ingredients, including but not limited to non-psychoactive cannabinoids and NSAIDs in a variety of ready-to-drink consumer retail beverage products. Additional claims granted to this patent also include the treatment of neurological diseases such as Parkinson’s disease, Human Immunodeficiency Virus (“HIV”), Alzheimer’s, and Schizophrenia (https://ibn.fm/Sni6V).

Through its four subsidiary companies, Lexaria has explored various sectors such as cannabidiol for hypertension, oral nicotine for reduced risk and antiviral drugs for COVID-19 and other infectious diseases. The progress so far has also allowed them to sub-license its DehydraTECH technology worldwide for delivering fat-soluble active molecules and drugs, thereby increasing the number of people who benefit from this technology and the number of lives impacted by it.

Lexaria remains committed to advancing its studies and expanding the indications and efficacy of its DehydraTECH technology. Through these efforts, it looks to benefit significantly from the CBD industry, projected to be valued at $111.8 billion by 2030 (https://ibn.fm/OP74n). In addition, Lexaria also looks to capitalize on the growing cardiovascular drugs market, which is projected to be valued at $107.8 billion by 2025, up from $96.1 billion in 2022 (https://ibn.fm/SWk5U).

As it pushes for the approval of additional patents and the licensing of its technology, the company looks to grow its market share significantly while redefining drug delivery platforms. 

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About TinyGems

TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.

To receive SMS text alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems Los Angeles, California www.TinyGems.com 310.299.1717 Office Editor@TinyGems.com

TinyGems is part of the InvestorBrandNetwork